NVAX
Novavax, Inc.
NVAX
Novavax, Inc.
Novavax NASDAQ: NVAX outlined its strategy to expand the use of its Matrix-M adjuvant platform through licensing partnerships, internal research programs and commercialization alliances, with manageme
Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Shares of Novavax Inc. (NASDAQ:NVAX) are trading higher Monday morning. The stock is extending its 30% monthly gains as investors respond positively to regulatory approvals across major jurisdictions
The news headliners this week included renewed tariff tensions , highly anticipated Nvidia (NVDA) earnings, and Friday's speech from Fed Chair Kevin Warsh , as the annual Jackson Hole, Wyoming sympos
COVID-19 remains a public health challenge, particularly among older adults and high-risk populations 1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable toler
Drug stock Novavax Inc (NASDAQ:NVAX) is trading 2.8% lower at $9.18 this afternoon, pulling back from yesterday's surge to six-week highs.
Moderna Inc (NASDAQ:MRNA) is powering up the Nasdaq this morning, last seen126.5% higher to trade at $142.61.
Novavax NASDAQ: NVAX reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in its Sanofi partnership, expanding use of its Matrix-M adjuvant pl
Novavax is significantly undervalued post-COVID, with a current enterprise value around $716 million and a promising pipeline led by Matrix-M. NVAX's Matrix-M adjuvant is a core value driver, validate